Get started
Author

Julien Gautier

Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
2009 · M.P. Sablin, S. Negrier, et al. · The Journal of Urology · 154
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
2016 · Olivier Mir, Claire Cropet, et al. · The Lancet Oncology · 127
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR
2020 · Souad Assaad, Virginie Avrillon, et al. · European Journal of Cancer · 122
PDF
Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients
2007 · M. P. Sablin, L. Bouaita, et al. · Journal of Clinical Oncology · 74
PALLIA ‐10, a screening tool to identify patients needing palliative care referral in comprehensive cancer centers: A prospective multicentric study ( PREPA ‐10)
2019 · Yann Molin, Caroline Gallay, et al. · Cancer Medicine · 55
PDF
Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol
2022 · Pierre Leblond, Maura Massimino, et al. · Frontiers in Neurology · 40
PDF
Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23
2021 · Peter Hau, Didier Frappaz, et al. · Cancers · 24
PDF
Severe post-artesunate delayed onset anaemia responding to corticotherapy: a case report
2017 · Delphine Lebrun, Thierry Floch, et al. · Journal of Travel Medicine · 22
Characteristics, management and outcome of Herpes Simplex and Varicella-Zoster virus encephalitis: a multicentre prospective cohort study
2024 · Léa Poussier, Alexandra Mailles, et al. · Clinical Microbiology and Infection · 21
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
2023 · Jerome Fayette, Claire Cropet, et al. · Journal of Clinical Oncology · 16
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
2021 · Christelle de la Fouchardière, Yann Godbert, et al. · European Journal of Cancer · 15
PDF
Vasculitides and glomerulonephritis associated withStaphylocococcus aureusinfective endocarditis: cases reports and mini-review of the literature
2020 · Aurélie Brunet, Gautier Julien, et al. · Annals of Medicine · 11
PDF
Predictive factors associated with high‐flow nasal cannula success for COVID ‐19‐related acute hypoxemic respiratory failure
2021 · Antoine Goury, Jean‐Adoumngar Moussanang, et al. · Health Science Reports · 10
PDF
Severe Intraabdominal Hypertension in Critically Ill COVID-19 Patients With Acute Kidney Injury
2021 · Vincent Dupont, Claire Gamblin, et al. · CHEST Journal · 9
PDF
The European Society of Paediatric Oncology Ependymoma-II program Core-Plus model: Development and initial implementation of a cognitive test protocol for an international brain tumour trial
2019 · S. Thomas, D. Reynolds, et al. · European Journal of Paediatric Neurology · 9
Functional outcome after infectious encephalitis: a longitudinal multicentre prospective cohort study
2024 · Pierre Fillâtre, Pierre Fillâtre, et al. · Clinical Microbiology and Infection · 8
Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).
2015 · Jean-Yves Blay, Mathieu Molimard, et al. · Journal of Clinical Oncology · 8
Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative study
2022 · Gisele Chvetzoff, Magali Girodet, et al. · BMJ Open · 5
PDF
Clinical benefit of adding cyanoacrylate glue during PICC line insertion compared to standard procedure in outpatient cancer patients: Results from the randomized prospective trial PICCandGLUE
2025 · Benjamin Figari, Norvène Driffort, et al. · The Journal of Vascular Access · 4
PDF
Pulmonary adverse events related to idelalisib therapy: A single centre experience
2018 · Caroline Migault, Delphine Lebrun, et al. · Journal of Chemotherapy · 4
REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.
2022 · Mehdi Brahmi, Julien Gautier, et al. · Journal of Clinical Oncology · 3
A Randomized Multicentre Phase Ii Study of Pazopanib Plus Best Supportive Care (Bsc) Vs Bsc Alone in Metastatic Gastrointestinal Stromal Tumors (Gist) Resistant to Imatinib and Sunitinib
2014 · J-Y. Blay, J. Domont, et al. · Annals of Oncology · 3
LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib
2024 · A. Le Cesne, C. Cropet, et al. · Annals of Oncology · 2
LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.
2020 · Axel Le Cesne, Claire Cropet, et al. · Journal of Clinical Oncology · 2
Analysis of characteristics in patients (pts) with metastatic renal cell cancer (MRCC) who achieved a prolonged benefit from sunitinib or sorafenib
2008 · S. Négrier, M. Gross-Goupil, et al. · Journal of Clinical Oncology · 2
Works count: 43
Citation count: 756
H-index: 11
I10-index: 13
Year
Topic
Type